Launch of messenger RNA sequencing analysis service using mass spectrometry.

Announcement of the Start of Messenger RNA Sequence Analysis Service Using Mass Spectrometry - Establishing New Technology to Support Drug Development and Quality Assurance.

Our company (hereinafter referred to as "TRC") has launched a messenger RNA (hereinafter referred to as "mRNA") nucleotide sequence analysis service using mass spectrometry under original conditions that we have established. mRNA is being applied to various pharmaceuticals, including the novel coronavirus vaccine. To ensure the quality of mRNA-based pharmaceuticals, it is necessary to confirm that the mRNA has the nucleotide sequence as designed. However, current common analytical methods result in the loss of information about chemically modified bases during the preprocessing stage. In response, TRC has established a technique to analyze the nucleotide sequence of mRNA, including chemically modified bases, by fragmenting mRNA with a molecular weight of over one million using enzymes and measuring it with mass spectrometry. The service utilizing this technology will contribute to the quality assurance of mRNA-based pharmaceuticals.

others